Table 2.
HLA-B*81:01, HLA-B*39:10, and other B7 allelic restricted sequence variations in and proximal to the TL9 epitope and putative compensatory mutationsa
| PIDb | wpic | TL9 mutations |
Other mutations |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| El77 | T180 | Q182 | T186 | L188 | T190 | H219 | I223 | A248 | M250 | I256 | ||
| CAP129 | 2 | – | – | T | – | – | – | – | H | T | – | – |
| B*81:01 | 23 | – | – | T | – | – | – | – | H | T | – | – |
| 32 | – | – | S | – | – | – | – | H | T | – | – | |
| 37 | – | S | – | – | – | – | H | T | – | – | ||
| 42 | – | – | S | – | – | – | – | H | T | – | – | |
| 54 | – | – | S | – | – | – | – | H | T | – | – | |
| 106 | – | – | S | – | – | – | – | H | T | – | – | |
| CAP222 | 56 | – | – | – | – | – | – | – | A | – | – | – |
| B*81:01 | 70 | – | – | – | – | – | – | – | A | – | – | – |
| 83 | – | – | S (6/9) | – | – | – | – | A | – | – | V | |
| 95 | – | – | S (1/6) | – | – | – | – | A | – | – | V | |
| 108 | – | – | S (3/11) | – | – | – | – | A | – | – | V (3/11) | |
| 108 | D | A | S | S (1/11) | – | – | – | A | – | – | – | |
| 108 | D | – | S | S (7/11) | – | – | – | V (2/7) | – | – | – | |
| 122 | D | – | S | S (13/13) | – | – | – | V 13/13 | – | – | – | |
| 133 | D | – | S | S | – | – | – | V (13/13) | – | – | – | |
| 148 | D | – | S | S | – | – | – | V | – | – | – | |
| 161 | D | – | S | S | – | – | – | V | – | – | – | |
| 174 | D | – | S | S | – | – | – | V (13/13) | – | – | – | |
| 190 | D | – | S | S | – | – | – | V | – | – | – | |
| CAP225 | 50 | – | – | – | – | – | – | – | – | – | – | – |
| B*81:01 | 61 | – | – | S (10/15) | – | – | – | – | – | – | – | V (10/15) |
| 74 | – | – | S | – | – | – | – | – | – | – | V | |
| 85 | – | – | S (3/15) | – | – | – | – | – | – | – | V (3/15) | |
| 98 | – | – | S | – | – | – | – | – | – | – | V | |
| 117 | – | – | S | – | – | – | – | – | – | – | V | |
| 130 | – | – | S | – | – | – | – | – | – | – | V | |
| 145 | – | – | S | – | – | – | – | – | – | – | V | |
| 158 | – | – | S | – | – | – | – | – | – | – | V | |
| 171 | – | – | S | – | – | – | – | – | – | – | V | |
| 183 | – | – | S | – | – | – | – | – | – | – | V | |
| CAP277 | 16 | – | – | – | – | – | – | – | – | – | I | – |
| B*81:01 | 41 | – | – | – | – | – | – | – | – | – | I | – |
| 46 | – | – | – | – | – | – | – | – | – | I | – | |
| 50 | – | – | H | – | – | – | – | – | – | I | – | |
| 54 | – | – | T | – | – | – | – | – | – | I | – | |
| 58 | – | – | T | – | – | – | – | – | – | I | – | |
| 71 | – | – | A | – | – | – | – | – | – | I | – | |
| 84 | – | – | S | – | – | – | – | – | – | I | – | |
| 97 | – | – | S (3/13) | – | – | – | – | – | – | I (3/13) | – | |
| 97 | – | – | S | S (6/13) | – | – | – | – | – | – (6/13) | – | |
| 97 | – | – | – | – | – | – | – | – | – | – (4/13) | – | |
| 110 | – | – | S | S | – | – | – | – | T | – | – | |
| 123 | – | – | S | S | – | – | – | – | T | – | – | |
| 137 | – | – | S | S | – | – | – | – | T | – | – | |
| CAP262 | 70 | – | – | – | – | – | – | – | – | – | – | – |
| B*81:01 | 84 | – | – | – | – | – | – | – | – | – | – | – |
| B*42:01 | 95 | – | – | – | – | – | – | – | – | – | – | – |
| 109 | – | – | – | – | – | – | – | – | – | – | – | |
| 122 | – | – | – | – | – | – | – | – | – | – | – | |
| 136 | – | – | – | – | – | – | – | – | – | – | – | |
| CAP278 | 9 | D | – | S | S | – | – | – | V | – | – | – |
| B*39:10 | 54 | D | – | S | S | – | – | – | V | – | – | – |
| 85 | D | – | S | S | – | – | Q | V | – | – | – | |
| CAP289 | 8 | – | – | A | – | – | – | – | V | – | – | V |
| B*39:10 | 24 | – | – | A | – | – | – | – | V | – | – | V |
| 28 | – | – | G | – | – | – | – | V | – | – | V | |
| 41 | – | – | G | – | – | – | – | V | – | – | V | |
| CAP061 | 14 | – | – | – | – | – | – | Q | V | – | – | – |
| B*42:01 | 33 | – | – | – | – | – | – | Q | V | – | – | – |
| C*08:02 | 51 | – | – | – | – | – | – | Q | V | – | – | – |
| 76 | – | – | – | – | F | – | Q | V | – | I | – | |
| 102 | – | – | – | – | – | – | – | V | – | – | – | |
| CAP282 | 11 | – | – | – | – | – | – | – | – | – | – | V |
| B*42:01 | 35 | – | – | – | – | – | – | – | – | – | – | V |
| 53 | – | – | T | – | – | – | – | – | – | – | V | |
a
The commonly evolving amino acid residues are indicated in lowercase italics in the peptide 176-SeGATPqDLNtML-188. –, No residue substitution or else the incoming residue is indicated; ND, not done or not available. Where applicable, the ratio of the number of mutations detected/total is indicated in parentheses.
b
PID, participant identification number.
c
wpi, weeks postinfection.